Search research articles

Search research articles

Related Experiment Videos

Haemoglobin-based oxygen carriers.

K D Vandegriff¹

¹Sangart, Inc., 11199 Sorrento Valley Rd, Ste. L, San Diego, CA 92121, USA. kvandegriff@sangart.com

Expert Opinion on Investigational Drugs

|November 4, 2000

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CO-MP4, a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats.

British journal of pharmacology·2008

Same author

The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers.

Biophysical chemistry·2001

Same author

Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model.

Journal of applied physiology (Bethesda, Md. : 1985)·1998

Same author

Arterial blood pressure responses to cell-free hemoglobin solutions and the reaction with nitric oxide.

The Journal of biological chemistry·1998

Same author

Hemoglobin-oxygen equilibrium curves measured during enzymatic oxygen consumption.

Analytical biochemistry·1998

Same author

Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated.

Biophysical chemistry·1998

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Haemoglobin-based oxygen carriers face challenges in clinical trials, with some discontinued due to adverse events. Ongoing research focuses on improving efficacy and safety for blood replacement therapies.

Area of Science:

Biotechnology
Biomaterials Science
Hematology

Background:

High demand for blood replacement therapies due to transfusion risks and blood shortages.
Cell-free hemoglobin requires modification for circulation retention in blood replacement products.
Development of hemoglobin-based oxygen carriers (HBOCs) addresses critical medical needs.

Purpose of the Study:

To review the development and clinical trial status of HBOCs.
To identify challenges and adverse events associated with different HBOC classes.
To highlight the need for improved understanding of HBOCs' efficacy and safety.

Main Methods:

Review of three classes of HBOCs: intramolecular cross-linked, intermolecular polymerised, and surface conjugated.
Analysis of clinical trial outcomes, including Phase III results.

Related Experiment Videos

Examination of reported adverse events and efficacy data.

Main Results:

Two cross-linked HBOCs discontinued in Phase III due to adverse events and mortality.
Three polymerised HBOCs are in ongoing Phase III trials.
Surface-conjugated HBOCs are in preclinical evaluation; cross-linked and polymerised products show safety but struggle with efficacy.
Common adverse effect is a haemodynamic response causing increased vascular resistance.

Conclusions:

HBOC development faces significant safety and efficacy hurdles, particularly regarding haemodynamic responses.
Further research into HBOCs' mechanisms of action is crucial for defining their clinical utility.
New HBOC designs aim to optimize blood flow, tissue perfusion, and oxygenation.